This trial is testing two drugs, Osimertinib and Amivantamab, to treat a specific type of lung cancer. The study focuses on adults whose cancer has certain genetic changes and has either advanced locally or spread. Osimertinib works by stopping cancer cells from growing, while Amivantamab helps the immune system attack these cells. Osimertinib is a standard treatment for non-small cell lung cancer with EGFR mutations, and Amivantamab targets EGFR exon 20 insertion mutations, showing promise in early trials.